Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats

American Journal of Nephrology

Volumn 31, Issue 3, 2010, Pages 262-272

  Hayden, Melvin R ^a   Habibi, Javad ^a,b   Whaley Connell, Adam ^a,b   Sowers, Dilek ^a   Johnson, Megan ^a   Tilmon, Roger ^a   Jain, Deepika ^a   Ferrario, Carlos ^c   Sowers, James R ^a,b  

^a University of Missouri   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

Megalin; NADPH oxidase; Proximal tubule cell

Indexed keywords

3 NITROTYROSINE; ALBUMIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MEGALIN; N ACETYL BETA GLUCOSAMINIDASE; NEBIVOLOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL STRUCTURE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENDOSOME; IMMUNOHISTOCHEMISTRY; KIDNEY PROXIMAL TUBULE; LYSOSOME; MALE; MITOCHONDRION; MOLECULAR WEIGHT; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TRANSGENIC RAT; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BENZOPYRANS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ETHANOLAMINES; FIBROSIS; HYPERTENSION, RENAL; KIDNEY TUBULES, PROXIMAL; LDL-RECEPTOR RELATED PROTEIN 2; LYSOSOMES; MALE; MICROSCOPY, ELECTRON; OXIDATIVE STRESS; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RENIN; VACUOLES;

EID: 75149120673     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000278757     Document Type: Article

References (51)

1. Go AS, Chertow GM, Fan D, McCulloch DE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr, Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber MA, Franklin S, Henriquez M, Kopyt N, Louis GT, Saklayen M, Stanford C, Walworth C, Ward H, Wiegmann T, ALLHAT Collaborative Research Group: Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: 172-180.
3. Sarafidis PA, Whaley-Connell A, Sowers JR, Bakris GL: Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr 2006; 1: 58-65.
4. Sowers JR: Metabolic risk factors and renal disease. Kidney Int 2007; 71: 719-720.
5. Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996; 7: 2495-2508.
6. Okada H, Kalluri R: Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr Mol Med 2005; 5: 467-474.
7. Hayden MR, Chowdhury NA, Witte L, Sowers JR: Microalbuminuria and proximal tubule remodeling in the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1: 107-114.
8. Birn H, Christensen EI: Renal albumin absorption in physiology and pathology. Kidney Int 2006; 69: 440-449.
9. Hayden MR, Chowdhury NA, Cooper SA, Whaley-Connell A, Habibi J, Witte L, Wiedmeyer C, Manrique CM, Lastra G, Ferrario C, Stump C, Sowers JR: Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2007; 292:F861-F867.
10. Russo LM, Sandoval RM, McKee M, Osicka TM, Collins AB, Brown D, Molitoris BA, Comper WD: The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int 2007; 71: 504-513.
11. Baines RJ, Brunskill NJ: The molecular interactions between filtered proteins and proximal tubular cells in proteinuria. Nephron Exp Nephrol 2008; 110:e67-e71.
12. Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM: Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol 2008; 295:F1589-F1600.
13. Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, Brown D: Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009; 20: 489-494.
14. Jarad G, Miner JH: Albumin, where art thou? J Am Soc Nephrol 2009; 20: 455-457.
15. Christensen EI, Verroust PJ, Nielsen R: Receptor- mediated endocytosis in renal proximal tubule. Pflugers Arch 2009; 458: 1039-1048.
16. Russo LM, Sandoval RM, McKee M, Osicka TM, Collins AB, Brown D, Molitoris BA, Comper WD: The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int 2007; 71: 504-513.
17. Guo DF, Tardif V, Ghelima K, Chan JS, Ingelfinger JR, Chen X, Chenier I: A novel angiotensin II type 1 receptor-associated protein induces cellular hypertrophy in rat vascular smooth muscle and renal proximal tubular cells. J Biol Chem 2004; 279: 21109-21120.
18. Caruso-Neves C, Kwon SH, Guggino WB: Albumin endocytosis in proximal tubule cells is modulated by angiotensin II through an AT2 receptor-mediated protein kinase B activation. Proc Natl Acad Sci USA 2005; 102: 17513-17518.
19. Li XC, Carretero OA, Navar LG, Zhuo JL: AT1 receptor-mediated accumulation of extracellular angiotensin II in proximal tubule cells: role of cytoskeleton microtubules and tyrosine phosphatases. Am J Physiol Renal Physiol 2006; 291:F375-F383.
20. Kobori H, Nangaku M, Navar LG, Nishiyama A: The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-257.
21. Verroust PJ, Birn H, Nielsen R, Kozyraki R Christensen EI: The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology. Kidney Int 2002; 62: 745-756.
22. Christensen EI, Nielsen R: Role of megalin and cubilin in renal physiology and pathology. Rev Physiol Biochem Pharmacol 2007; 158: 1-22.
23. Mitchell KD, Jacinto SM, Mullins JJ: Proximal tubular fluid, kidney, and plasma levels of angiotensin II in hypertensive Ren-2 transgenic rats. Am J Physiol Renal Physiol 1997; 273:F246-F253.
24. Zhuo J, Ohishi M, Mendelsohn FA: Roles of AT1 and AT2 receptors in the hypertensive Ren-2 gene transgenic rat kidney. Hypertension 1999; 33: 347-353.
25. Hartner A, Porst M, Klanke B, Cordasic N, Veelken R, Hilgers KF: Angiotensin II formation in the kidney and nephrosclerosis in the Ren-2 hypertensive rats. Nephrol Dial Transplant 2006; 21: 1778-1795.
26. Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, Gallagher PE, Tallant EA, Cooper SA Link CD, Ferrario C, Sowers JR: Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006; 291:F1308-F1314.
27. Patni H, Mathew JT, Luan L, Franki N, Chander PH, Singhal PC: Aldosterone promotes proximal tubular cell apoptosis: role of oxidative stress. Am J Physiol Renal Physiol 2007; 293:F1065-F1071.
28. Whaley-Connell A, Habibi J, Wei Y, Gutweiler A, Jellison J, Wiedmeyer CE, Ferrario CM, Sowers JR: Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2009; 296: F1013-F1022.
29. Hosojima M, Sato H, Yamamoto K, Kaseda R, Soma T, Kobayashi A, Suzuki A, Kabasawa H, Takeyama A, Ikuyama K, Iino N, Nishiyama A, Thekkumkara TJ, Takeda T, Suzuki Y, GejyoF, Saito A: Regulation of megalin expression in cultured proximal tubule cells by angiotensin II type 1A receptorand insulin-mediated signaling cross talk. Endocrinology 2009; 150: 871-878.
30. Wei Y, Whaley-Connell AT, Chen K, Habibi J, Uptergrove GME, Clark SE, Stump CS, Ferrario CM, Sowers JR: NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007; 50: 384-391.
31. Nishioka T, Callahan MF, Li P, Ferrario CM, Ganten D, Morris M: Increased central angiotensin and osmotic responses I the Ren-2 transgenic rat. Hypertension 1999; 33: 385-388.
32. Augustyniak RA, Tuncel M, Zhang W, Toto RD, Victor RG: Sympathetic overactivity as a cause of hypertension in chronic renal failure. J Hypertens 2002; 20: 3-9.
33. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ: Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-1576.
34. Whaley-Connell A, Habibi J, Johnson M, Timon R, Rehmer N, Rehmer J, Wiedmeyer C, Ferrario CM, Sowers JR: Nebivolol reduces proteinuria and renal NADPH oxidasegenerated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol 2009; 30: 354-360.
35. Tzemos N, Lim PO, MacDonald TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, doubleblind, crossover study. Circulation 2001; 104: 511-514.
36. Kalinowski L, Dobrucki LW, Szczepanska- Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T: Third-generation β- Blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107: 2747-2752.
37. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, Lo Cascio V, Cominacini L: Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589-596.
38. 1- adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther 2008; 26: 189-202.
39. Georgescu A, Pluteanu F, Flonta ML, Badila E, Dorobantu M, Popov D: The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol 2005; 508: 159-166.
40. Pires MJ, Rodriquez-Pena AB, Arevalo M, Cenador B, Evangelista S, Esteller A, Sanchez- Rodriguez A, Colaco A, Lopez-Novoa JM: Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. Hypertension 2007; 25: 2486-2496.
41. Toprak O, Cirit M, Tanrisev M, Yazici C, Canoz O, Sipahiogiu M, Uzum A Ersoy R, Sozmen EY: Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant 2008; 23: 853-859.
42. Gschwend S, Haug MB, Nierhaus M, Schulz A, Vetter R, Kossmehl P, Orzechowski HD, Scholze J, Rothermund L, Kreutz R: Shortterm treatment with a β-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure. Life Sci 2009; 85: 431-437.
43. Bosomworth MP, Aparicio SR, Hay AW: Urine N-acetyl- D -glucosaminidase - a marker of tubular damage? Nephrol Dial Transplant 1999; 14: 620-626.
44. Hayden MR, Whaley-Connell A, Sowers JR: Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: paying homage to the podocyte. Am J Nephrol 2005; 25: 553-569.
45. Whaley-Connell A, Habibi J, Nistala R, Cooper SA, Karuparthi PR, Hayden MR, Rehmer N, DeMarco VG, Andresen BT, Wei Y, Ferrario C, Sowers JR: Attenuation of angiotensin II-mediated NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 2008; 51: 474-480.
46. Christensen EI, Willnow TE: Essential role of megalin in renal proximal tubule for vitamin homeostasis. J Am Soc Nephrol 1999; 10: 2224-2236.
47. Nielsen R, Courtoy PJ, Jacobsen C, Dom G, Lima WR, Jadot M, Willnow TE, Devuyst O, Christensen EI: Endocytosis provides a major alternative pathway for lysosomal biogenesis in kidney proximal tubular cells. Proc Natl Acad Sci USA 2007; 104: 5407-5412.
48. Brooks C, Wei Q, Cho SG, Dong Z: Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 2009; 119: 1275-1285.
49. Brooks C, Wei Q, Cho SG, Dong Z: Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 2009; 119: 1275-1285.
50. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P, Wright JT Jr, Waterhouse B, Lukas MA, Anderson KM, Bell DS, GEMINI Investigators: Differential effects of β-blockers on albuminuria in patients with type 2 diabetes. Hypertension 2005; 46: 1309-1315.
51. Hart PD, Bakris GL: Should β-blockers be used to control hypertension in people with chronic kidney disease? Semin Nephrol 2007; 27: 555-564.